3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Breast Neoplasms
27
Neoplasm Metastasis
9
Stomach Neoplasms
7
Ovarian Neoplasms
4
Colorectal Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Esophageal Neoplasms
3
Endometrial Neoplasms
3
Sarcoma
2
Salivary Gland Neoplasms
2
Recurrence
2
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
Melanoma
2
HER2-positive Gastric Cancer
2
Carcinoma, Renal Cell
2
Brain Neoplasms
2
Advanced Solid Tumor
2
Advanced Breast Cancer
2
Adenocarcinoma
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Unresectable Locally Recurrent Breast Cancer
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Testicular Neoplasms
1
Interventions
Paclitaxel
4
pembrolizumab
3
Cisplatin
3
Doxorubicin
2
Carboplatin
2
Brachytherapy
2
Biopsy
2
trastuzumab deruxtecan
1
sacituzumab govitecan
1
relugolix
1
dostarlimab
1
dehydroftorafur
1
belzutifan
1
Watchful Waiting
1
Vaginal Smears
1
VMBP protocol
1
Ultrasound, High-Intensity Focused, Transrectal
1
Transurethral Resection of Prostate
1
Taxes
1
Sutures
1
Standard of Care
1
Radiotherapy, Intensity-Modulated
1
Pregnancy Tests
1
Practice Guidelines as Topic
1
Platinum
1
Papanicolaou Test
1
Oxaliplatin
1
Mitozytrex
1
Mitomycin
1
Magnetic Resonance Spectroscopy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Uterine Neoplasms
×
trastuzumab deruxtecan
×
Clear all
NCT06989112
2026-05-06
DE-01
AstraZeneca
Phase 3
Recruiting
600 enrolled